Skip to content
LLL231231231

Drawing based on the label description. No photo yet.

“mg tablets are white to off-white colored, capsule shaped, biconvex, bevel edged scored uncoated tablet debossed with "L" on one side of score line and "231" on another side of score line and plain on other side”

L 231 pill

Pill with imprint L 231 is white, capsule, 17 mm and has been identified as Metoprolol Tartrate and Hydrochlorothiazide 100 mg / 50 mg. It is used for high blood pressure and quitting smoking. It is supplied by Alembic Pharmaceuticals Limited.

Metoprolol Tartrate and Hydrochlorothiazide 100 mg / 50 mg

Imprint
L 231
Strength
Metoprolol Tartrate 100 mg / Hydrochlorothiazide 50 mg
Used for
High blood pressure and quitting smoking
Color
White
Shape
Capsule / oblong
Size
17 mm
Score
Breaks into 2 pieces
Form
Tablet
Manufacturer
Alembic Pharmaceuticals Limited
Drug class
Beta blocker (heart and blood pressure medicine)
NDC
46708-117, 46708-117-30, 46708-117-10, 46708-117-50, 62332-117, 62332-117-30, 62332-117-31, 62332-117-71

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Metoprolol Tartrate and Hydrochlorothiazide pills and guides

What is Metoprolol Tartrate and Hydrochlorothiazide used for?

Metoprolol Tartrate and Hydrochlorothiazide is used for high blood pressure and quitting smoking.

Medicine type
Beta blocker (heart and blood pressure medicine); thiazide diuretic (water pill)
Official uses from the US prescribing label

Metoprolol tartrate and hydrochlorothiazide tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents.

Limitation of Use

Metoprolol tartrate and hydrochlorothiazide tablets is not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, therapy with the fixed combination may be more convenient than with the separate components.

From the FDA-approved label on DailyMed (published Apr 10, 2025).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows L and the other side shows 231.
  • It is white, capsule, 17 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Metoprolol Tartrate, Hydrochlorothiazide

Inactive: Microcrystalline Cellulose, Sodium Starch Glycolate Type A Potato, Silicon Dioxide, Povidone, Unspecified, Anhydrous Lactose, Starch, Corn, Magnesium Stearate

Also distributed by

Alembic Pharmaceuticals Inc.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Metoprolol Tartrate and Hydrochlorothiazide pills